BLBruce T. Lamb

Bruce T. Lamb

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bruce T. Lamb has a total of 309 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plcg2 Deficiency Leads to Sex‐Associated Divergent Effects on Glial Transcriptomes

    by Kelly A. Hartigan, Luke C. Dabin, Holly N. Kersey, Nur Jury‐Garfe, Ahmad Daniel Sharify, Byungwook Kim, Bruce T. Lamb, Stephanie J. Bissel, Cristian Lasagna‐Reeves, Jungsu Kim

    Plcg2 encodes an intracellular phospholipase C signaling enzyme expressed predominately in microglia in the brain. Genome‐wide association studies implicate PLCG2 in Alzheimer's disease (AD) risk and loss of Plcg2 alters amyloid pathology in mouse models. However, the physiological impact of Plcg2 loss remains unclear. To address this gap, we performed single‐cell RNA sequencing (scRNA‐seq) of wild‐type, heterozygous, and homozygous Plcg2 ‐deficient mouse brains in the absence of amyloid or tau pathology. Our analyses generated a comprehensive, publicly available atlas of glial transcriptomic states across genotypes and sexes. Genotype‐associated changes in microglia and astrocytes were enriched in neurodegenerative disease‐related pathways, as well as oxidative phosphorylation and proteostasis pathways. Genotype‐by‐sex interaction and sex‐stratified analyses revealed divergent regulation of many of these pathways in males and females, while co‐expression and cell–cell communication analyses identified additional sex‐associated differences in glial signaling networks. Overall, these data provide a framework for understanding how variation in PLCG2 function may shape glial biology and modify pathways relevant to neurodegenerative disease in a sex‐associated manner.

  • Open Access

    Molecular Glue Degraders Enhance CAPRIN1‐Dependent Lysosomal Degradation of APP and Reduce Amyloid β in Alzheimer's Disease

    by Sunghan Jung, Xu Wang, Bin Liu, Raktim Roy, Nancy Jaiswal, Ratan K. Rai, Yuichiro Takagi, Cen Gao, Lifan Zeng, Ho‐Yin Lo, et al.

    The amyloid cascade involving the production and deposition of amyloid β (Aβ) peptides derived from amyloid precursor protein (APP) is a leading hypothesis in the pathogenesis of Alzheimer's disease (AD). However, disease‐modifying therapies targeting this cascade remain an unmet challenge. Here, we identify small molecules that degrade APP and reduce Aβ production through a targeted protein degradation strategy. Using genetically engineered APP cell models and induced pluripotent stem cell (iPSC)‐derived neurons from patients with AD, we demonstrate that cytoplasmic activation/proliferation‐associated protein 1 (CAPRIN1) is expressed in neurons and physically interacts with APP. Screening of a CAPRIN1‐targeted compound library identified compound 0043, which promotes intracellular APP degradation and reduces extracellular Aβ release. Structure–activity relationship optimization of 0043 derivatives yielded compound 0152 with improved potency and blood–brain barrier permeability. In AD iPSC‐derived neurons, these compounds enhance CAPRIN1–APP interactions and promote CAPRIN1‐dependent APP degradation through the endolysosomal pathway. CAPRIN1 is predominantly expressed in neurons in AD postmortem brains and iPSC‐derived brain organoids. Systemic administration of compound 0152 significantly reduced APP levels, Aβ production, and amyloid burden in 5xFAD mice. These findings establish CAPRIN1‐dependent, lysosome‐targeted molecular glue degraders as a potential APP‐targeted therapeutic strategy for AD.

  • Open Access

    PLCG2 modulates TREM2 expression and signaling in response to Alzheimer's disease pathology

    by Evan J. Messenger, Sydney A. Baar, Logan M. Bedford, Andy P. Tsai, Peter Bor‐Chian Lin, Chloe A. Ferguson, Guixiang Xu, Abigail Wallace, Gary E. Landreth, Bruce T. Lamb, et al.

    BACKGROUND: Phospholipase C gamma 2 (PLCG2) is an intracellular effector of microglial cell surface receptors, including triggering receptor expressed on myeloid cells 2 (TREM2). Variants which alter PLCG2 activity impact Alzheimer's disease (AD) risk, but the effects of PLCG2 deficiency in AD remain unclear.METHODS: 5xFAD mice were crossed with PLCG2‐ and TREM2‐deficient mice to assess the role of PLCG2 in response to amyloid pathology. Human bulk RNA‐sequencing data were used to validate findings in AD patients.RESULTS: In 5xFAD mice, the absence of PLCG2 resulted in reduced TREM2 expression and impaired microglial associations with amyloid beta plaques. Transcriptomic analysis revealed perturbations in immune‐related pathways shared between PLCG2 and TREM2 deficiencies, as well as distinct differences. Human transcriptomics revealed positive correlations between PLCG2 and TREM2 independent of pathological scores.DISCUSSION: PLCG2 is a critical component of TREM2 signal transduction and may play an upstream role in TREM2 regulation. These findings clarify the mechanisms of risk and protective PLCG2 variants.Highlights: The role of phospholipase C gamma 2 (PLCG2) deficiency in response to amyloid beta (Aβ) pathology was investigated in 5xFAD mice and with human cortical transcriptomics. PLCG2 deficiency significantly reduces triggering receptor expressed on myeloid cells 2 (TREM2) expression, while TREM2 deficiency increases PLCG2 expression. PLCG2 expression predicts TREM2 expression in human cortex independent of pathology. PLCG2 and TREM2 deficiencies similarly impair microglial responses to Aβ plaques, exacerbate neuronal pathology, and impair gene expression associated with immune responses. PLCG2 deficiency confers distinct transcriptional perturbations from TREM2 deficiency. PLCG2 may play an upstream role in the regulation of the TREM2‐mediated immune response.


  • Open Access

    CYP1B1-RMDN2 Alzheimer’s disease endophenotype locus identified for cerebral tau PET

    by Kwangsik Nho, Shannon L. Risacher, Liana G. Apostolova, Paula J. Bice, Jared R. Brosch, Rachael Deardorff, Kelley Faber, Martin R. Farlow, Tatiana Foroud, Sujuan Gao, et al.

    Determining the genetic architecture of Alzheimer’s disease pathologies can enhance mechanistic understanding and inform precision medicine strategies. Here, we perform a genome-wide association study of cortical tau quantified by positron emission tomography in 3046 participants from 12 independent studies. The CYP1B1-RMDN2 locus is associated with tau deposition. The most significant signal is at rs2113389, explaining 4.3% of the variation in cortical tau, while APOE4 rs429358 accounts for 3.6%. rs2113389 is associated with higher tau and faster cognitive decline. Additive effects, but no interactions, are observed between rs2113389 and diagnosis, APOE4, and amyloid beta positivity. CYP1B1 expression is upregulated in AD. rs2113389 is associated with higher CYP1B1 expression and methylation levels. Mouse model studies provide additional functional evidence for a relationship between CYP1B1 and tau deposition but not amyloid beta. These results provide insight into the genetic basis of cerebral tau deposition and support novel pathways for therapeutic development in AD.


  • Open Access

    Network analysis identifies strain-dependent response to tau and tau seeding-associated genes

    by Dominic J. Acri, Yanwen You, Mason D. Tate, Hande Karahan, Pablo Martinez, Brianne McCord, A. Daniel Sharify, Sutha John, Byungwook Kim, Luke C. Dabin, et al.

    Previous research demonstrated that genetic heterogeneity is a critical factor in modeling amyloid accumulation and other Alzheimer’s disease phenotypes. However, it is unknown what mechanisms underlie these effects of genetic background on modeling tau aggregate-driven pathogenicity. In this study, we induced tau aggregation in wild-derived mice by expressing MAPT. To investigate the effect of genetic background on the action of tau aggregates, we performed RNA sequencing with brains of C57BL/6J, CAST/EiJ, PWK/PhJ, and WSB/EiJ mice (n = 64) and determined core transcriptional signature conserved in all genetic backgrounds and signature unique to wild-derived backgrounds. By measuring tau seeding activity using the cortex, we identified 19 key genes associated with tau seeding and amyloid response. Interestingly, microglial pathways were strongly associated with tau seeding activity in CAST/EiJ and PWK/PhJ backgrounds. Collectively, our study demonstrates that mouse genetic context affects tau-mediated alteration of transcriptome and tau seeding. The gene modules associated with tau seeding provide an important resource to better model tauopathy.


  • Open Access

    Network analysis reveals strain-dependent response to misfolded tau aggregates

    by Dominic J. Acri, Yanwen You, Mason D. Tate, Brianne McCord, A. Daniel Sharify, Sutha John, Hande Karahan, Byungwook Kim, Luke C. Dabin, Stéphanie Philtjens, et al.

    Mouse genetic backgrounds have been shown to modulate amyloid accumulation and propagation of tau aggregates. Previous research into these effects has highlighted the importance of studying the impact of genetic heterogeneity on modeling Alzheimer’s disease. However, it is unknown what mechanisms underly these effects of genetic background on modeling Alzheimer’s disease, specifically tau aggregate-driven pathogenicity. In this study, we induced tau aggregation in wild-derived mice by expressing MAPT (P301L). To investigate the effect of genetic background on the action of tau aggregates, we performed RNA sequencing with brains of 6-month-old C57BL/6J, CAST/EiJ, PWK/PhJ, and WSB/EiJ mice (n=64). We also measured tau seeding activity in the cortex of these mice. We identified three gene signatures: core transcriptional signature, unique signature for each wild-derived genetic background, and tau seeding-associated signature. Our data suggest that microglial response to tau seeds is elevated in CAST/EiJ and PWK/PhJ mice. Together, our study provides the first evidence that mouse genetic context influences the seeding of tau. Graphical SUMMARY: Seeding of tau predates the phosphorylation and spreading of tau aggregates. Acri and colleagues report transcriptomic responses to tau and elevated tau seeds in wild-derived mice. This paper creates a rich resource by combining genetics, tau biosensor assays, and transcriptomics.

  • Open Access

    Genetic Variants of Phospholipase C-γ2 Confer Altered Microglial Phenotypes and Differential Risk for Alzheimer’s Disease

    by Andy P. Tsai, Chuanpeng Dong, Peter Bor-Chian Lin, Adrian L. Oblak, Gonzalo Viana Di Prisco, Nian Wang, Nicole Hajicek, Adam J. Carr, Emma K. Lendy, Oliver Hahn, et al.

    Summary: Genetic association studies have demonstrated the critical involvement of the microglial immune response in Alzheimer’s disease (AD) pathogenesis. Phospholipase C-gamma-2 (PLCG2) is selectively expressed by microglia and acts in many immune receptor signaling pathways. In AD, PLCG2 is induced uniquely in plaque-associated microglia. A genetic variant of PLCG2 , PLCG2 P522R , is a mild hypermorph that attenuates AD risk. We report the identification of a PLCG2 variant, PLCG2 M28 L , associated with loss-of-function and confers increased AD risk. PLCG2 P522R attenuates disease in an amyloidogenic murine AD model, whereas PLCG2 M28L exacerbates the plaque burden associated with altered phagocytosis and Aβ clearance. The variants bidirectionally modulate disease pathology by inducing distinct transcriptional programs that identify microglial subpopulations associated with protective or detrimental phenotypes. In summary, these findings identify PLCG2 M28L as a new AD risk variant and demonstrate that PLCG2 variants can differentially orchestrate microglial responses in AD pathogenesis that can be therapeutically targeted. Graphical Highlights: A genetic variant of PLCG2, M28L, is associated with an increased risk for Alzheimer’s disease (AD) In an amyloidogenic AD mouse model, PLCG2M28L exacerbates disease pathogenesis Conversely, PLCG2P522R, a protective PLCG2 variant, attenuates AD pathogenesis The PLCG2 variants uniquely alter the microglial transcriptome and phenotypes


  • Open Access

    Triggering receptor expressed on myeloid cells 2 deficiency exacerbates injury-induced inflammation in a mouse model of tauopathy

    by Atsuko Katsumoto, Olga N. Kokiko-Cochran, Shane M. Bemiller, Guixiang Xu, Richard M. Ransohoff, Bruce T. Lamb

    Traumatic brain injury (TBI) promotes several Alzheimer’s disease-like pathological features, including microtubule-associated protein tau (MAPT) accumulation within neurons. Macrophage activation in the injured hTau mouse model of tauopathy raises the question whether there is a relationship between MAPT pathology and alterations in macrophage activation following TBI. Triggering receptor expressed on myeloid cells 2 (TREM2) is a critical regulator of microglia and macrophage phenotype, but its mechanisms on TBI remain unclear. To address the association with TREM2 in TBI and MAPT pathology, we studied TREM2 deficiency in hTau mice (hTau;Trem2-/-) 3 (acute phase) and 120 (chronic phase) days after experimental TBI. At three days following injury, hTau;Trem2-/- mice exhibited reduced macrophage activation both in the cortex and hippocampus. However, to our surprise, hTau;Trem2-/- mice exposed to TBI augments macrophage accumulation in the corpus callosum and white matter near the site of tissue damage in a chronic phase, which results in exacerbated axonal injury, tau aggregation, and impaired neurogenesis. We further demonstrate that TREM2 deficiency in hTau injured mice promotes neuronal dystrophy in the white matter due to impaired phagocytosis of apoptotic cells. Remarkably, hTau;Trem2-/- exposed to TBI failed to restore blood-brain barrier integrity. These findings imply that TREM2 deficiency accelerates inflammation and neurodegeneration, accompanied by attenuated microglial phagocytosis and continuous blood-brain barrier (BBB) leakage, thus exacerbating tauopathy in hTau TBI mice.


  • Open Access

    CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease

    by Shweta S. Puntambekar, Miguel Moutinho, Peter Bor-Chian Lin, Vaishnavi Jadhav, Danika Tumbleson-Brink, Ananya Balaji, Martin Alvarado Benito, Guixiang Xu, Adrian Oblak, Cristian A. Lasagna-Reeves, et al.

    Background: Despite its identification as a key checkpoint regulator of microglial activation in Alzheimer’s disease, the overarching role of CX3CR1 signaling in modulating mechanisms of Aβ driven neurodegeneration, including accumulation of hyperphosphorylated tau is not well understood. Methodology: Accumulation of soluble and insoluble Aβ species, microglial activation, synaptic dysregulation, and neurodegeneration is investigated in 4- and 6-month old 5xFAD;Cx3cr1+/+ and 5xFAD;Cx3cr1−/− mice using immunohistochemistry, western blotting, transcriptomic and quantitative real time PCR analyses of purified microglia. Flow cytometry based, in-vivo Aβ uptake assays are used for characterization of the effects of CX3CR1-signaling on microglial phagocytosis and lysosomal acidification as indicators of clearance of methoxy-X-04+ fibrillar Aβ. Lastly, we use Y-maze testing to analyze the effects of Cx3cr1 deficiency on working memory. Results: Disease progression in 5xFAD;Cx3cr1−/− mice is characterized by increased deposition of filamentous plaques that display defective microglial plaque engagement. Microglial Aβ phagocytosis and lysosomal acidification in 5xFAD;Cx3cr1−/− mice is impaired in-vivo. Interestingly, Cx3cr1 deficiency results in heighted accumulation of neurotoxic, oligomeric Aβ, along with severe neuritic dystrophy, preferential loss of post-synaptic densities, exacerbated tau pathology, neuronal loss and cognitive impairment. Transcriptomic analyses using cortical RNA, coupled with qRT-PCR using purified microglia from 6 month-old mice indicate dysregulated TGFβ-signaling and heightened ROS metabolism in 5xFAD;Cx3cr1−/− mice. Lastly, microglia in 6 month-old 5xFAD;Cx3cr1−/− mice express a ‘degenerative’ phenotype characterized by increased levels of Ccl2, Ccl5, Il-1β, Pten and Cybb along with reduced Tnf, Il-6 and Tgfβ1 mRNA. Conclusions: Cx3cr1 deficiency impairs microglial uptake and degradation of fibrillar Aβ, thereby triggering increased accumulation of neurotoxic Aβ species. Furthermore, loss of Cx3cr1 results in microglial dysfunction typified by dampened TGFβ-signaling, increased oxidative stress responses and dysregulated pro-inflammatory activation. Our results indicate that Aβ-driven microglial dysfunction in Cx3cr1−/− mice aggravates tau hyperphosphorylation, neurodegeneration, synaptic dysregulation and impairs working memory.